1119P Targeted treatment and immunotherapy in older patients with advanced melanoma: A single institution real-life experience

Abstract

Our multicenter retrospective analysis included 499 patients treated with anti-PD-1 agents (nivolumab or pembrolizumab) between 2017 and 2019. 208 patients were aged <65 years, 218 patients were aged 65-79 years, and 73 patients were aged 80-100 years. We analysed the efficacy and toxicity of anti-PD-1 therapy at the age of 80-100 years compared to the age of 65-79 years and to <65 years. Baseline parameters, response rate (overall response rate -ORR), best response, progression-free survival (PFS), melanoma-specific survival (MSS) and immunerelated adverse events were analysed. The KaplaneMeier method was used to estimate PFS and MSS, Cox regression, t test, and chi-square test were used for statistical analysis.Results: Baseline parameters were comparable. There was no statistically significant difference between the groups aged <65 years, aged 65-79 years and aged 80-100 years of MSS (p¼0.2781), PFS (p¼0.5373), the number of responses to treatment (p¼0.155) and the occurrence of irAE (p¼ 0.821). In the multivariate analysis, the presence of brain metastases, elevated LDH levels, and the occurrence of at least one irAE had a statistically significant impact on OS and PFS. The age, gender, BRAF mutation, primary lesion location, type of anti-PD-1 therapy had no statistically significant effect on MSS and PFS in the multivariate analysis. Toxicity for all groups was similar. Immune related adverse events in grade 3 or 4 were reported in 5%, 5.5% and 4% of patients in the groups aged <65 years, aged 65-79 years and aged 80-100 years, respectively.Conclusions: Anti PD-1 therapy in octogenarian and nonagenarian metastatic melanoma patients has similar efficacy and toxicity compared to patients aged <65 years and 65-79 years. The patient's age cannot be the reason for disqualification from anti-PD-1 treatment.Legal entity responsible for the study: Bo_ zena Cybulska-Stopa.

Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer

“…18 19 Results from the phase I/II ILLUMINATE-204 trial demonstrated the safety and activity of intratumoral IMO-2125, also named tilsotolimod, in combination with systemic ICI ipilimumab in patients with anti-PD1 refractory advanced melanoma. 20 Interestingly, the antitumor activity was observed in both injected (enestic) and noninjected (anenestic) lesions (NCT02644967).…”